Accentia Faces Investor Suit Over Lymphoma Vaccine
The directors of Accentia Biopharmaceuticals Inc. subsidiary Biovest International Inc. lied to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine that Biovest was developing, artificially inflating both companies' stock...To view the full article, register now.
Already a subscriber? Click here to view full article